Introduction

ETM

Experimental and Therapeutic Medicine

1792-0981 1792-1015

D.A. Spandidos

ETM-27-4-12461

10.3892/etm.2024.12461

Articles

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Han

Yan

1 * Li

Ya-Feng

2 * Ye

Chao-Wei

3 * Gu

Yao-Yang

3 * Chen

Xiao

4 Gu

Qian

3 Xu

Qiang-Qiang

3 Wang

Xian-Ming

3 He

Su-Mei

5 Wang

Dong-Dong

1Department of Emergency Medicine, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221116, P.R. China 2Department of Pharmacy, Feng Xian People's Hospital, Xuzhou, Jiangsu 221700, P.R. China 3Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China 4School of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China 5Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, P.R. China

Correspondence to: Mrs Su-Mei He, Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, 1 Lijiang Road, Suzhou, Jiangsu 215153, P.R. China 13852029591@163.com hehe8204@163.com

Dr Dong-Dong Wang, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, P.R. China 13852029591@163.com

^*Contributed equally

04 2024

28 02 2024

27 4

173

10 07 2023 13 02 2024

2024

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The dose-dependent pharmacological response to dapagliflozin in patients with type 2 diabetes mellitus (T2DM) with regard to weight loss remain unknown. The aim of the present study was to investigate the effects of dapagliflozin on weight loss in patients with T2DM. A total of 8,545 patients with T2DM from 24 randomized controlled trials reported in the literature were selected for inclusion in the study. Data from these trials were analyzed using maximal effect (E_max) models with nonlinear mixed effects modeling; the evaluation index was the body weight change rate from baseline values. Patients treated with 2.5 mg/day dapagliflozin exhibited an E_max of -3.04%, and the time taken for therapy to reach half of the E_max (ET₅₀) was estimated to be 30.8 weeks for patients treated with this dose. Patients treated with 5, 10 and 20 mg/day dapagliflozin exhibited E_max values of -6.57, -4.12 and -3.23%, respectively, and their ET₅₀ values were estimated to be 27.3, 20.4 and 4.23 weeks, respectively. The data indicated ideal linear relationships between individual predictions and observations, suggesting the optimal fitting of the final models. The present study is the first systematic analysis of the effect of dapagliflozin on weight loss in patients with T2DM. The application of dapagliflozin at 5 mg/day exhibited a greater weight loss effect compared with the other doses used, and the weight loss onset time shortened as the dose of dapagliflozin increased.

effect dapagliflozin weight loss type 2 diabetes mellitus evidence-based practice

Funding: The study was supported by The Innovative Practice Training Program for Students of Jiangsu Higher Education Institutions (grant no. 202210313053Z), The National Innovative Practice Training Program for Students of Higher Education Institutions (grant no. 202210313053), The Xuzhou Special Fund for Promoting Scientific and Technological Innovation (grant no. KC21257), The Initializing Fund of Xuzhou Medical University (grant nos. RC20552111 and RC20552222), The Fusion Innovation Project of Xuzhou Medical University (grant nos. XYRHCX2021011 and XYRHCX2022005), Jiangsu Province Education Science Planning Project (grant no. C/2022/01/36), Xuzhou Medical University Labor Education Special Support Project (grant no. X1d202209), Jiangsu Province Higher Education Informatization Research Topic (grant no. 2023JSETKT136) and Xuzhou Medical University Research Topic of Higher Education Teaching Reform (grant no. Xjyzrd202304).

Introduction

It is estimated that the global prevalence of diabetes is currently 463 million worldwide and will increase to 700 million by 2045(1). Type 2 diabetes mellitus (T2DM), a condition in which patients experience hyperglycemia due to impaired insulin action and insufficient insulin secretion, is the most common type of diabetes worldwide (1). In addition, patients with T2DM often present with hypertension, dyslipidemia, atherosclerotic disease and obesity (2,3). It has been reported that >50% of patients with T2DM are obese (3,4). Patients with T2DM who are overweight or obese have a higher risk of cardiovascular disease and higher mortality rate, which are vital determinants of T2DM prognosis (4,5). Therefore, it is crucial to improve the management of T2DM in patients who are overweight or obese (6).

Dapagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor and was the first drug with this mechanism to be approved for the treatment of T2DM. It is considered to be an important treatment option as an adjunct to diet and exercise for the improvement of glycemic control in adult patients with T2DM (7). In addition, dapagliflozin can cause a modest reduction in weight (7). The weight loss achieved with dapagliflozin is clinically meaningful in terms of improving overall health outcomes and reducing the risk of complications associated with T2DM (7).

However, the extent to which dapagliflozin causes weight reduction and the dose-dependent pharmacological response to dapagliflozin in patients with T2DM with regard to weight loss remain unknown. Therefore, the present study aimed to explore the dose-dependent weight loss response to dapagliflozin in patients with T2DM.

Materials and methods <sec> <title>Included data

The data of patients with T2DM treated with dapagliflozin were extracted from published articles, and the details of patients assigned to the treatment or control groups were obtained from the selected literature (8-31). These studies had all been approved by the ethics committee of each participating center (8-31). The inclusion criteria for the present study were as follows: i) Patients with T2DM, ii) dapagliflozin treatment, iii) randomized controlled trial (RCT), iv) availability of body weight information and v) availability of the exact dosage and duration of therapy with dapagliflozin. No additional specific criteria were required to be met. The source, grouping, dapagliflozin dosage, duration of treatment, sample size and patient age were extracted from these published articles.

In order to eliminate the potential baseline effect, the present study calculated the body weight change rate from baseline for use as an evaluation index. The equation (I) used was as follows.

E_time is weight at a specific time and E_base is weight at baseline.

Model establishment

The effects of dapagliflozin on weight loss in patients with T2DM varied with time and eventually reached a plateau. Maximal effect (E_max) models were used to assess these effects. In addition, the actual effects of dapagliflozin on weight loss in patients with T2DM were assessed by subtracting the control effect from the sum effect using equations (II) and (III) as follows:

E_a,i,j represents the sum effect of dapagliflozin on weight loss in patients with T2DM; E_{b,i j} represents the weight loss in the control group of patients with T2DM; E_c,i,j represents the actual effect of dapagliflozin on weight loss in patients with T2DM; i represents a specific study; j represents the time point of the study; ET₅₀ is the duration of treatment required to reach half the E_max; Ɛ_i,j represents the residual error of study i with time j; and N_i,j represents the sample size in study i at time point j. Ɛ_i,j was weighted by sample size and assumed to be normally distributed, with a mean of 0 and variance of σ²/(N_i,j/100).

The variabilities observed between studies were described using additive error or exponential error models. The equations used (IV)-(VII) were as follows:

In these equations, F_max represent E_max, FT₅₀ represent ET₅₀, m represents a specific study; n represents the time point of the study; η_1,n and η_2,n represent the inter-study variability, when available, which was assumed to be normally distributed, with a mean of 0 and variance of ω_1,i², ω_2,i², respectively.

Furthermore, categorical and continuous covariates (source, weight and age) were evaluated using equations (VIII)-(X):

P_pati represents the value of an individual parameter; P_Typi represents the value of a typical parameter; COV represents the covariate; COV_m represents the median value of COV; and θ_c represents a correction coefficient.

Statistical analysis

Nonlinear mixed effects modeling software (NONMEM^®; edition 7; ICON Development Solutions Ltd.) was used to establish the model and conduct statistical analysis. A change in the objective function value (OFV), which is a function that quantifies the difference between predicted values from the model and the actual observed data, was used as the criterion for covariate inclusion, which was the criterion to determine the fitting of the model. When the OFV was decreased [>3.84; χ², α=0.05, degrees of freedom (d.f.)=1], the inclusion criterion was met. When the OFV was increased (>6.63; χ², α=0.01, d.f.=1), significance was achieved in the final model. Our previous studies were mainly based on the methodology used in the present study, and indicated that the present method was reliable and acceptable (32-35).

Model validation

Individual predictions were compared with observations in individual plots and used to evaluate the final model. Prediction-corrected visual predictive check (VPC) plots were used to assess the predictive effectiveness of the final model.

Results <sec> <title>Included studies

A total of 24 RCTs, which included 8,545 patients with T2DM, were selected for analysis (8-31). These studies included 44 dapagliflozin treatment groups, which comprised 5 with a dose of 2.5 mg/day, 12 with a dose of 5 mg/day, 23 with a dose of 10 mg/day, and 4 with a dose of 20 mg/day. Drug safety at high doses was evaluated and no significant adverse reactions were found; in particular, no serious adverse events associated with the liver, kidney or pancreas were reported in these studies (8-31). In addition, in the included studies, the duration of dapagliflozin treatment was 12-104 weeks, and the mean age range of the patients with T2DM was 49.9-68.0 years (Table I).

Modeling and validation

The actual dapagliflozin effect on weight loss in patients with T2DM is shown in Table II. Four E_max models were established, one for each dose of dapagliflozin (2.5, 5, 10 and 20 mg/day) to investigate the effect of the treatment on weight loss in patients with T2DM. The calculated values of E_max and ET₅₀ were as follows: 2.5 mg/day, -3.04% and 30.8 weeks, respectively; 5 mg/day dapagliflozin, -6.57% and 27.3 weeks, respectively; 10 mg/day dapagliflozin, -4.12% and 20.4 weeks, respectively; and 20 mg/day dapagliflozin, -3.23% and 4.23 weeks, respectively. Information was obtained for all 8,545 patients with T2DM and it was not found that the clinicopathological characteristics of the patients may have influenced their weight loss outcomes.

Models were constructed based on the E_max and ET₅₀ values for the 2.5, 5, 10 and 20 mg/day doses of dapagliflozin. The effects of these doses on weight loss in patients with T2DM are described in equations (XI)-(XIV), respectively:

E represents the effect of dapagliflozin on the weight loss of patients with T2DM, and time is the duration of dapagliflozin treatment. Notably, these equations show that the only factor that ultimately affects body weight is the dose and duration of dapagliflozin.

Fig. 1 presents plots of individual predictions compared with observations for patients treated with 2.5, 5, 10 and 20 mg/day dapagliflozin. The data indicate ideal linear relationships between individual predictions and observations, suggesting the optimal fitting of the final models. Plots for individuals treated with 2.5, 5, 10 and 20 mg/day dapagliflozin are shown in Fig. 2. These also demonstrate the optimal predictive ability of the models. VPC plots (Fig. 3) were established using data derived from patients treated with 2.5, 5, 10 and 20 mg/day dapagliflozin. The majority of the observed data fell within the 95% prediction intervals generated from the simulated data, which indicated the predictive power of the final models.

Dose-dependent pharmacological response to dapagliflozin

Fig. 4 indicates a dose-dependent pharmacological effect of dapagliflozin on weight loss in patients with T2DM. Fig. 4A indicates the relationship between E_max and dapagliflozin dosage, and Fig. 4B that between ET₅₀ and dapagliflozin dosage. Based on these results, it can be deduced that among the four doses, 5 mg/day dapagliflozin exhibited the greatest weight loss effect, and the order of efficacy from high to low was as follows: 5 mg/day >10 mg/day >20 mg/day >2.5 mg/day. The onset time of weight loss reduced as the dose increased, and the order of onset from fast to slow was as follows: 20 mg/day >10 mg/day >5 mg/day >2.5 mg/day.

Discussion

Dapagliflozin is a SGLT2 inhibitor, which is used as a therapeutic strategy for the treatment of diabetes (7). The SGLT2 protein is specifically expressed in the renal tubular proximal S1 segment, where it mediates glucose reabsorption in the early proximal tubule; it is responsible for ~90% of glucose reabsorption in the kidney (7). SGLT2 inhibitors specifically inhibit the activity of SGLT2 and lower renal glucose reabsorption in the proximal convoluted tubule leading to increased urinary glucose excretion (7,36-38). The recommended initial dosage of dapagliflozin in the United States and China is 5 mg, which is rapidly absorbed following oral administration and enables the maximal plasma concentrations to be achieved in 2 h (7). In addition, the oral bioavailability following the administration of 10 mg dapagliflozin is 78%, and the mean half-life is 12.9 h (7). Dapagliflozin has been accepted as a monotherapy or adjuvant therapeutic strategy for T2DM in the European Union, United States and China (7).

Various clinical trials have verified that dapagliflozin is effective in reducing glycated hemoglobin, fasting plasma glucose and body weight with a low incidence of hypoglycemic events (7,39,40). In addition, dapagliflozin monotherapy (5-10 mg/day) is effective in achieving glucose control, and patients exhibit optimal adherence to the treatment due to it being easy to use (7,41-43). However, patients with T2DM often develop obesity (2,3); obese patients have an elevated risk of cardiovascular disease and mortality. Therefore, it is crucial to improve the management of overweight or obese patients with T2DM (6). Fortunately, in addition to improving the control of blood glucose, dapagliflozin is also able to reduce the weight of patients with T2DM, thus providing benefits to patients with T2DM from multiple perspectives.

However, the dose-dependent pharmacological response to dapagliflozin with regard to weight loss in patients with T2DM is unknown; specific clinical guidance for dapagliflozin in the promotion of weight loss in patients with T2DM is lacking. Therefore, the purpose of the present study was to probe the effects of dapagliflozin on weight loss in patients with T2DM. A total of 24 RCT studies containing 8,545 patients with T2DM were included for analysis in the present study. These included 44 dapagliflozin dose groups, of which 5 received a dose of 2.5 mg/day, 12 a dose of 5 mg/day, 23 a dose of 10 mg/day, and 4 a dose of 20 mg/day.

The E_max model was used to evaluate the dose-dependent pharmacological response of weight loss to dapagliflozin in patients with T2DM. In addition, in order to determine the actual weight loss effect of dapagliflozin in T2DM, the control effect was subtracted from the sum effect. Moreover, since RCTs were included, the experimental and control groups from the same source were essentially identical in terms of patient demographics, comorbidities and other factors that may influence weight loss in patients with T2DM. The literature data were processed by subtracting the possible effect on weight in the control group from that in the experimental group in order to obtain the actual weight loss effect of dapagliflozin in T2DM.

Finally, four E_max models were established, one for each dose of dapagliflozin (2.5, 5, 10 and 20 mg/day). The models represent the effect of dapagliflozin on weight loss in patients with T2DM. Patients treated with 2.5, 5, 10 and 10 mg/day dapagliflozin demonstrated E_max values of -3.04, -6.57, -4.12 and 3.23%, respectively and ET₅₀ values of 30.8, 27.3, 20.4 and 4.23 weeks, respectively. The efficacy of dapagliflozin in the induction of weight loss in patients with T2DM was highest with a 5 mg/day dose, followed by 10, 20 and 2.5 mg/day, respectively. We hypothesize that the reason for the least favorable effect being achieved with 2.5 mg is that this dose is insufficient, while the optimal efficacy was obtained at 5 mg. However, the underlying mechanism of the effects of dapagliflozin on body weight require further study in the future. The onset time of weight loss was fastest with a dosage of 20 mg/day and slowed gradually as the dosage decreased from 10 to 2.5 mg/day. In addition, information was obtained from all 8,545 patients with T2DM and it was not found that different methodology, data collection methods, sample sizes, generalizability or other factors had any influence on weight loss outcomes.

The present study has certain objective limitations. Firstly, the included studies were all published, and included those with negative results or studies that did not show a significant effect of dapagliflozin on weight loss; However, unpublished literature data were not included, which may result in potential bias. Secondly, the deviations from the mean were not analyzed. Thirdly, the safety profile of the drug, particularly that associated with the liver, kidney and pancreas was not included or thoroughly considered. However, the doses explored were all administered in clinical trials or as recommended in the instructions of use, and the general safety was optimal and acceptable. It is important to note that the long-term effects require further assessment. Nevertheless, the security of long-term dapagliflozin use appears to be acceptable. Fioretto et al (44) reported that dapagliflozin treatment for ≤104 weeks was well tolerated in older patients. Although older patients treated with dapagliflozin, experienced more renal adverse events than placebo-treated patients, the majority of these events were non-serious small transient changes in serum creatinine. Durán-Martínez et al (45) reported that dapagliflozin had an appropriate safety profile in patients with T1DM following the careful selection of participants and implementation of strategies to reduce the risk of diabetic ketoacidosis, and the treatment also led to clinical improvements in this population.

In conclusion, to the best of our knowledge, the present study is the first to analyze the dose-dependent pharmacological effect of dapagliflozin on weight loss in patients with T2DM. Of the four doses used, 5 mg/day dapagliflozin exhibited the greatest weight loss effect, and the onset time of weight loss accelerated with increasing dose. The detailed mechanism underlying the effects of dapagliflozin on body weight will be investigated in future studies. In particular, proteomic investigations may be carried out using animal experiments to determine the specific signaling pathway of dapagliflozin.

Acknowledgements

Not applicable.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

The study was conceived and designed by SMH and DDW. Collection of data was performed by YH, YFL, CWY, YYG, XC, QG, QQX and XMW. Data analysis and interpretation were performed by DDW, YH, YFL, CWY and YYG. The manuscript was written by YH, YFL, CWY and YYG. All authors read and approved the final version of the manuscript: YH and DDW confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Nicholson

Ghazal Asswad

Wilding

Dapagliflozin for the treatment of type 2 diabetes mellitus-an update

Expert Opin Pharmacother22230323102021

34281456

10.1080/14656566.2021.1953471

González-Muniesa

Mártinez-González

Després

Matsuzawa

Loos

RJF

Moreno

Bray

Martinez

Obesity

Nat Rev Dis Primers3170342017

28617414

10.1038/nrdp.2017.34

Iglay

Hannachi

Joseph Howie

Engel

Moore

Rajpathak

Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

Curr Med Res Opin32124312522016

26986190

10.1185/03007995.2016.1168291

Einarson

Acs

Ludwig

Panton

Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017

Cardiovasc Diabetol17832018

29884191

10.1186/s12933-018-0728-6

American Diabetes Association

8. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2020

Diabetes Care43 (Suppl 1)S89S972020

31862751

10.2337/dc20-S008

Uneda

Kawai

Yamada

Kinguchi

Azushima

Kanaoka

Toya

Wakui

Tamura

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Sci Rep11101662021

33986377

10.1038/s41598-021-89620-7

Feng

Wang

Lyu

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Medicine (Baltimore)98e165752019

31348290

10.1097/MD.0000000000016575

Aso

Kato

Sakurai

Kishi

Shimizu

Jojima

Iijima

Maejima

Shimomura

Usui

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

Int J Clin Pract73e133352019

30810254

10.1111/ijcp.13335

Bailey

Gross

Hennicken

Iqbal

Mansfield

List

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial

BMC Med11432013

23425012

10.1186/1741-7015-11-43

Cefalu

Leiter

de Bruin

Gause-Nilsson

Sugg

Parikh

Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

Diabetes Care38121812272015

25852208

10.2337/dc14-0315

Grandy

Hashemi

Langkilde

Parikh

Sjöström

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

Diabetes Obes Metab166456502014

24443876

10.1111/dom.12263

Henry

Murray

Marmolejo

Hennicken

Ptaszynska

List

Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

Int J Clin Pract664464562012

22413962

10.1111/j.1742-1241.2012.02911.x

Iacobellis

Gra-Menendez

Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity

Obesity (Silver Spring)28106810742020

32352644

10.1002/oby.22798

Mansfield

T'joen

Iqbal

Ptaszynska

List

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study

Clin Ther3684100.e92014

24378206

10.1016/j.clinthera.2013.11.002

Kaku

Kiyosue

Inoue

Ueda

Tokudome

Yang

Langkilde

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise

Diabetes Obes Metab16110211102014

24909293

10.1111/dom.12325

Kohan

Fioretto

Tang

List

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Kidney Int859629712014

24067431

10.1038/ki.2013.356

Lambers Heerspink

de Zeeuw

Wie

Leslie

List

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes Obes Metab158538622013

23668478

10.1111/dom.12127

Leiter

Cefalu

de Bruin

TWA

Gause-Nilsson

Sugg

Parikh

Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

J Am Geriatr Soc62125212622014

24890683

10.1111/jgs.12881

List

Woo

Morales

Tang

Fiedorek

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

Diabetes Care326506572009

19114612

10.2337/dc08-1863

Mathieu

Ranetti

Ekholm

Cook

Hirshberg

Chen

Hansen

Iqbal

Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes

Diabetes Care38200920172015

26246458

10.2337/dc15-0779

Matthaei

Bowering

Rohwedder

Sugg

Parikh

Johnsson

Study 05 Group

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Diabetes Obes Metab17107510842015

26212528

10.1111/dom.12543

Rosenstock

Hansen

Zee

Cook

Hirshberg

Iqbal

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

Diabetes Care383763832015

25352655

10.2337/dc14-1142

Rosenstock

Vico

Wei

Salsali

List

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

Diabetes Care35147314782012

22446170

10.2337/dc11-1693

Schumm-Draeger

Burgess

Korányi

Hruba

Hamer-Maansson

de Bruin

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: A 16-week randomized, placebo-controlled clinical trial

Diabetes Obes Metab1742512015

25200570

10.1111/dom.12387

Strojek

Yoon

Hruba

Elze

Langkilde

Parikh

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial

Diabetes Obes Metab139289382011

21672123

10.1111/j.1463-1326.2011.01434.x

Wilding

JPH

Norwood

T'Joen

Bastien

List

Fiedorek

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment

Diabetes Care32165616622009

19528367

10.2337/dc09-0517

Wilding

JPH

Woo

Rohwedder

Sugg

Parikh

Dapagliflozin 006 Study Group

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years

Diabetes Obes Metab161241362014

23911013

10.1111/dom.12187

Yamakage

Tanaka

Inoue

Odori

Kusakabe

Satoh-Asahara

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

J Diabetes Investig116536612020

31721467

10.1111/jdi.13179

Yang

Han

Min

Wang

Mansfield

T'Joen

Iqbal

Johnsson

Ptaszynska

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial

J Diabetes87968082016

26589253

10.1111/1753-0407.12357

Yang

Zhou

Kim

Zhao

Ptaszynska

Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial

J Diabetes105895992018

29215189

10.1111/1753-0407.12634

Zhang

Feng

List

Kasichayanula

Pfister

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight

Diabetes Obes Metab125105162010

20518806

10.1111/j.1463-1326.2010.01216.x

Wang

Mao

Chen

Analysis of time course and dose effect from metformin on body mass index in children and adolescents

Front Pharmacol126114802021

33981216

10.3389/fphar.2021.611480

Chen

Wang

Time course and dose effect of metformin on weight in patients with different disease states

Expert Rev Clin Pharmacol13116911772020

32940086

10.1080/17512433.2020.1822164

Chen

Wang

Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients

J Clin Pharm Ther461061132021

32974902

10.1111/jcpt.13260

Wang

Mao

Zhu

Wei

A machine-learning approach for predicting the effect of carnitine supplementation on body weight in patients with polycystic ovary syndrome

Front Nutr98512752022

36034907

10.3389/fnut.2022.851275

DeFronzo

Hompesch

Kasichayanula

Liu

Hong

Pfister

Morrow

Leslie

Boulton

Ching

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

Diabetes Care36316931762013

23735727

10.2337/dc13-0387

Gerich

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

Diabet Med271361422010

20546255

10.1111/j.1464-5491.2009.02894.x

Vallon

Platt

Cunard

Schroth

Whaley

Thomson

Koepsell

Rieg

SGLT2 mediates glucose reabsorption in the early proximal tubule

J Am Soc Nephrol221041122011

20616166

10.1681/ASN.2010030246

Kaku

Maegawa

Tanizawa

Kiyosue

Ide

Tokudome

Hoshino

Yang

Langkilde

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: An open-label study

Diabetes Ther54154332014

25341477

10.1007/s13300-014-0086-7

Zhang

Song

Dapagliflozin treatment for type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Diabetes Metab Res Rev302042212014

24115369

10.1002/dmrr.2479

Vallon

Thomson

Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition

Diabetologia602152252017

27878313

10.1007/s00125-016-4157-3

Wilson

Diabetes: Dapagliflozin: An insulin-independent, therapeutic option for type 2 diabetes mellitus

Nat Rev Endocrinol65312010

21080534

10.1038/nrendo.2010.134

Gilor

Niessen

SJM

Furrow

DiBartola

What's in a name? Classification of diabetes mellitus in veterinary medicine and why it matters

J Vet Intern Med309279402016

27461721

10.1111/jvim.14357

Fioretto

Mansfield

Ptaszynska

Yavin

Johnsson

Parikh

Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: A pooled analysis of phase IIb/III studies

Drugs Aging335115222016

27357173

10.1007/s40266-016-0382-1

Durán-Martínez

Azriel

Doulatram-Gamgaram

Moreno-Pérez

Pinés-Corrales

Tejera-Pérez

Merino-Torres

Brito-Sanfiel

Chico

Marco

Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study

Diabetes Metab501015012024

38061425

10.1016/j.diabet.2023.101501

Figure 1

Routine diagnostic plots of predictions and observations for different treatment groups. Plots for patients treated with (A) 2.5 mg/day, (B) 5 mg/day, (C) 10 mg/day and (D) 20 mg/day dapagliflozin are shown.

Figure 2

Individual plots of predictions and observations for different treatment groups. Plots for patients treated with (A) 2.5 mg/day, (B) 5 mg/day, (C) 10 mg/day and (D) 20 mg/day dapagliflozin are shown. DV, observed value; IPRED, individual predicted value; PRED, population predicted value; ID, study identity.

Figure 3

Prediction-corrected visual predictive check plots. Plots for patients treated with (A) 2.5 mg/day, (B) 5 mg/day, (C) 10 mg/day and (D) 20 mg/day dapagliflozin are shown. The median, 2.5 and 97.5% CI were simulated by the Monte Carlo method (n=1,000). CI, confidence interval; a-w, 44 dapagliflozin dose groups from 24 randomized controlled trials (8-31).

Figure 4

Pharmacological effect of dapagliflozin on weight loss. Relationships between (A) E_max and dapagliflozin dosage and (B) ET₅₀ and dapagliflozin dosage. E_max, maximal effect; ET₅₀, time taken to reach half the E_max.

Table I

Studies identified for analysis.

First author/s, year	Source	Groups	Dapagliflozin, mg/day	Duration of treatment, weeks	Body weight, kg mean median (SD); mean ± SD; (inter-quartile range); median [5-95^th percentile]	Patient no.	Age, years	(Refs.)
Iacobellis and Gra-Menendez, 2020	USA	Dapagliflozin	10	24	104(28)	50	52(9)	(13)
		Control	-	24	96.9(23)	50	51(11)
Yamakage et al, 2020	Japan	Dapagliflozin	5	24	80.5±22.6	27	58.4±13.0	(28)
		Control	-	24	79.0±16.3	27	60.7±11.9
Aso et al, 2019	Japan	Dapagliflozin	5	24	73.6 (61.9, 80.8)	33	-	(8)
		Control	-	24	74.9 (65.6, 81.6)	24	-
Yang et al, 2018	Asia	Dapagliflozin	10	24	71.1±12.0	139	56.5±8.4	(30)
		Control	-	24	72.4±13.1	133	58.6±8.9
Yang et al, 2016	Asia	Dapagliflozin	5	24	70.8±12.2	147	53.1±9.1	(29)
		Dapagliflozin	10	24	71.4±12.0	152	54.6±9.5
		Control	-	24	70.9±11.4	145	53.5±9.2
Matthaei et al, 2015	-	Dapagliflozin	10	52	88.6 (17.6)	108	-	(21)
		Control	-	52	90.1 (16.2)	108	-
Mathieu et al, 2015	-	Dapagliflozin	10	24	85.8±18.4	160	55.2±8.6	(20)
		Control	-	24	88.2±18.1	160	55.0±9.6
Cefalu et al, 2015	Europe, Asia, USA, Canada, and Argentina	Dapagliflozin	10	52	92.6 (20.5)	455	62.8 (7.0)	(10)
		Control	-	52	93.6 (19.5)	459	63.0 (7.7)
Rosenstock et al, 2015	USA	Dapagliflozin	10	24	87.1±18.0	179	53±10	(22)
		Control	-	24	88.0±18.7	176	55±10
Schumm-Draeger et al, 2015	Europe and South Africa	Dapagliflozin	2.5	16	92.49 (18.632)	100	58.3 (9.0)	(24)
		Dapagliflozin	5	16	93.62 (16.641)	99	55.3 (9.3)
		Dapagliflozin	10	16	90.58 (15.929)	99	58.5 (9.8)
		Control	-	16	88.82 (15.327)	101	58.5 (9.4)
Kaku et al, 2014	Japan	Dapagliflozin	5	24	65.81 (14.37)	86	58.6 (10.4)	(15)
		Dapagliflozin	10	24	69.70 (13.82)	88	57.5 (9.3)
		Control	-	24	65.96 (12.91)	87	60.4 (9.7)
Leiter et al, 2014	USA, Canada, Australia, Chile, Argentina and five European countries	Dapagliflozin	10	24	94.5±17.8	480	63.9±7.6	(18)
		Control	-	24	93.2±16.8	482	63.6±7.0
Grandy et al, 2014	Bulgaria, Czech Republic, Hungary, Poland and Sweden	Dapagliflozin	10	102	92.1 (14.1)	89	60.6 (8.2)	(11)
		Control	-	102	90.9 (13.7)	91	60.8 (6.8)
Ji et al, 2014	China, Korea and India	Dapagliflozin	5	24	68.89 (11.43)	128	53.0 (11.07)	(14)
		Dapagliflozin	10	24	70.92 (11.64)	133	51.2 (9.89)
		Control	-	24	72.18 (13.23)	132	49.9 (10.87)
Kohan et al, 2014	USA, Argentina, Canada, India, Mexico, Peru, Italy, Australia, France, Spain, Denmark, Puerto Rico and Singapore	Dapagliflozin	5	104	95.2±20.9	83	66±8.9	(16)
		Dapagliflozin	10	104	93.2±17.3	85	68±7.7
		Control	-	10	89.6±20.0	84	67±8.6
Wilding et al, 2014	Worldwide	Dapagliflozin	2.5	104	93.0 (16.7)	202	59.8 (7.6)	(27)
		Dapagliflozin	10	104	94.5 (16.8)	194	59.3 (8.8)
		Control	-	104	94.5 (19.8)	193	58.8 (8.6)
Lambers et al, 2013	Canada, Netherlands and USA	Dapagliflozin	10	12	93.2 (18.0)	24	53.7 (9.4)	(17)
		Control	-	12	96.2 (19.5)	25	58.0 (9.5)
Bailey et al, 2013	Argentina, Brazil, Canada, Mexico, and USA	Dapagliflozin	2.5	102	84.90 (17.77)	137	-	(9)
		Dapagliflozin	5	102	84.73 (16.26)	137	-
		Dapagliflozin	10	102	86.28 (17.53)	135	-
		Control	-	102	87.74 (19.24)	137	-
Rosenstock et al, 2012	Argentina, Canada, India, Mexico, Peru, China, Philippines and USA	Dapagliflozin	5	48	87.8±20.7	141	53.2±10.9	(23)
		Dapagliflozin	10	48	84.8±22.2	140	53.8±10.4
		Control	-	48	86.4±21.3	139	53.5±11.4
Henry et al, 2012	North America, Latin America, Europe and Asia	Dapagliflozin	5	24	84.1 (19.5)	194	51.7 (9.3)	(12)
		Dapagliflozin	10	24	88.4 (19.7)	211	51.0 (10.1)
		Control	-	24	87.2 (19.4)	208	52.7 (10.4)
Strojek et al, 2011	Czech Republic, Hungary, Republic of Korea, Philippines, Poland, Thailand and Ukraine	Dapagliflozin	2.5	24	81.89	154	59.9±10.14	(25)
		Dapagliflozin	5	24	81.00	142	60.2±9.73
		Dapagliflozin	10	24	80.56	151	58.9±8.32
		Control	-	24	80.94	145	60.3±10.16
Zhang et al, 2010	-	Dapagliflozin	10	12	86.6 [60.6, 115]	45	55.0[41.0,71.0]	(31)
		Dapagliflozin	20	12	86.6 [60.6, 115]	57	55.0[41.0,71.0]
		Control	-	12	89.8 [59.2, 122]	49	52.0[34.4,70.6]
		Dapagliflozin	10	12	104 [82.0, 120]	19	57.0[38.0,71.6]
		Dapagliflozin	20	12	104 [82.0, 120]	25	57.0[38.0,71.6]
		Control	-	12	95.7 [77.3, 113]	14	60.0[49.6,69.0]
Wilding et al, 2009	USA and Canada	Dapagliflozin	10	12	103.4±10.2	24	55.7±9.2	(26)
		Dapagliflozin	20	12	101.2±15.3	24	56.1±10.6
		Control	-	12	101.8±16.5	23	58.4±6.5
List et al, 2009	USA, Canada, Mexico and Puerto Rico	Dapagliflozin	2.5	12	90±20	59	55±11	(19)
		Dapagliflozin	5	12	89±17	58	55±12
		Dapagliflozin	10	12	86±17	47	54±9
		Dapagliflozin	20	12	88±18	59	55±10
		Control	-	12	89±18	54	54±9

Table II

Parameter estimates of the final models.

Model	Parameter	Estimate
A	E_max, %	-3.04
	ET₅₀, week	30.8
	ω_Emax	1.360
	ω_ET50	17.088
	Ɛ	0.062
B	E_max, %	-6.57
	ET₅₀, week	27.3
	ω_Emax	2.773
	ω_ET50	15.460
	Ɛ	0.100
C	E_max, %	-4.12
	ET₅₀, week	20.4
	ω_Emax	0.585
	ω_ET50	7.918
	Ɛ	0.327
D	E_max, %	-3.23
	ET₅₀, week	4.23
	ω_Emax	-
	ω_ET50	3.302
	Ɛ	0.010

Model A, patients treated with 2.5 mg/day dapagliflozin; model B, patients treated with 5 mg/day dapagliflozin; model C, patients treated with 10 mg/day dapagliflozin; D, patients treated with 20 mg/day dapagliflozin. E_max, maximal effect; ET₅₀, treatment duration to reach half of the _Emax; ω_Emax, interstudy variability of E_max; ω_ET50, interstudy variability of ET₅₀; Ɛ, residual error.